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ThalassemiaAbstract Patients with chronic hemolytic anemia like thalassemia and sickle cell anemia need
repeated blood transfusions which lead to iron overload and cellular damage especially in the heart
and liver. Classically, serum ferritin and liver biopsy have been used to monitor patient response to
chelation therapy. Magnetic resonance imaging (MRI) has been proved effective in detecting and
quantifying iron in the heart and liver.
Objective: To assess the accuracy of MRI T2* procedure in assessment of hepatic (LIC) and
myocardial iron concentration (MIC).
Methods: In 70 cases of monthly transfused patients, hepatic and myocardial iron overload was
measured by multibreath holds MRI T2* and compared to serum ferritin (a traditional marker
of iron overload).
Results: No signiﬁcant correlation was observed between serum ferritin level and cardiac T2* MRI
(p= 0.528, r= 0.077). However, a signiﬁcant correlation was observed between serum ferritin
and liver T2* MRI (p= 0.007, r= 0.318).
Conclusion: Routine evaluation of liver and heart iron content using MRI T2* is suggested to bet-
ter evaluate the hemosiderosis status in thalassemic and sickle cell patients.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Iron is an essential element that forms an important compo-
nent of metabolic and biological processes, but when present
in excess, it can produce tissue damage due to oxidative stress
1086 H.S. Fahmy et al.(15). Patients with thalassemia and some patients with sickle
cell disease (SCD) patients need regular blood transfusions
to survive beyond the second decade of life (3). Although
transfusions improve health and survival, the chronic adminis-
tration of large amounts of blood combined with extra vascu-
lar hemolysis and an increase in the intestinal absorption of
iron inevitably leads – despite chelation therapy – to signiﬁcant
hemosiderosis of all organs (16). Excess body iron may accu-
mulate in the liver, spleen, heart, bone marrow, pituitary, pan-
creas, and the central nervous system, causing damage to these
organs (9).
Iron overload cardiomyopathy (IOC) results from the accu-
mulation of iron in the myocardium, and it often occurs late
and can be hard to reverse once established and it is the leading
cause of death in patients receiving chronic blood transfusion
therapy (4,18). Unfortunately, signiﬁcant cardiac iron burden
can occur despite low liver iron concentration (7). There is
an important clinical need to reliably risk stratify patients
for the development of heart failure so that chelation therapy
can be intensiﬁed and cardiac morbidity averted (20).
Indirect markers of current cardiac iron overloading,
namely single measurements of serum ferritin and biopsy-
determined liver iron concentration are inadequate for identi-
fying myocardial iron deposition in the chronically transfused
patients (26).
Ferritin is a metalloprotein that is found in cells. It stores
and releases iron in a controlled manner. In normal individu-
als, a small amount appears in the circulation and in general
reﬂects the total body iron. Normal values of serum ferritin
for men and women are 12–300 ng/ml and 12–150 ng/ml,
respectively (2).
It is an acute phase reactant, and the serum levels may be
disproportionately greater than the degree of iron loading in
infections, inﬂammatory states, liver dysfunction and malig-
nancies (2).
However, magnetic resonance can exploit the paramagnetic
properties of tissue iron to provide direct, non-invasive iron
assessments, and clinically this has been achieved by assessing
the T2 and T2* relaxation parameters (24). Magnetic reso-
nance does not image the iron directly but instead images
water protons as they diffuse near iron deposits in the tissue
of interest (8). The iron acts as small magnets, destroying the
homogeneity of the magnetic ﬁeld in iron-laden tissues. The
moving water protons experience signiﬁcantly different mag-
netic proﬁles and became desynchronized from one another.
This causes the image to darken at a rate proportional to the
iron concentration (15).
This technique is simple, allowing rapid and reproducible
quantiﬁcation of myocardial and hepatic iron and therefore
allows pre-symptomatic detection of myocardial siderosis
(17). The T2* technique has the potential to become a non-
invasive standard technique in assessing tissue iron (13). In
our study, we also compared the MRI T2* results with serum
ferritin levels of patients on regular blood transfusion.
2. Methods
Since October 2012–September 2014, a prospective study of 70
patients referred for MRI assessment of cardiac and liver
siderosis at our institute has undergone a standardized imaging
protocol which includes measurement of cardiac and liver T2*.We studied 70 patients with B-thalassemia and sickle cell ane-
mia (34 females and 36 males; 65 thalassemia patients and 5
SCD), with a median age of 19.34 ± 9.34 (range: 5–49 years).
The exclusion criteria were as follows: patients younger than
5 years old as they did not receive enough transfusion to
develop hepatic or myocardial siderosis, and patients with
associated hepatitis B or C to avoid any other parenchymal
changes that could alter our results. Our patients did not have
history of other congenital or acquired liver disease. All
patients were on regular transfusion programme and on iron
chelation therapy for at least 18 months.
The present study considers the following parameters:
(a) Serum ferritin, (b) liver iron concentration, (c) liver and
myocardial T2 relaxation time.
Ethical committee approval to perform MRI T2* technique
and patients or guardians consents were obtained.
2.1. MRI technique
Magnetic resonance imaging studies were performed using a
1.5-T Espree system (Siemens Medical Systems). For the liver,
three transverse images were recorded using a body matrix
coil, visualizing the right liver lobe (L) and posterior vertebral
muscles (M) in the same slice. In order to measure the T2*
relaxation, Gradient echo sequence (GRE T2*) sequence with
12 different echo times (1.2–21.8 ms) was used to acquire
images. The ﬁeld of view was 250–450 mm (depends on the
patient body circumference) and the matrix was 128 · 192. In
order to reduce the scan time with phase FOV is reduced to
70%. Three images were obtained at the middle of the liver
with each slice acquired with patient instructed to hold their
breath. TR was 200 ms, ﬂip angle was 20 and slice thickness
was 8 mm. Acquisition time per slice was 10–15 s.
For the heart, three mid-ventricular short axis slice was
imaged with a slice thickness of 6 mm and a slice gap of
0.6 mm. Using body matrix coil, Gradient echo sequence
(T2*) with eight echo times (3.6–16 ms) was used to obtain
the images. The ﬁeld of view was 280–320 mm with the phase
FOV was between 60% and 80%. With Conventional white
blood technique prospective ECG triggering was used. The
image was acquired at the end diastolic phase where the heart
motion was minimal. The TR between each radiofrequency
was 20 ms. The matrix was 128 · 192. Acquisition time per
slice was 8–12 s.
Total scanning for the liver and heart T2* assessment was
completed within 10 min. This includes the setup time for
ECG, localizer scan and 6 Breath holds (three for the liver
and 3 for the heart). For analysis, the signal intensity of a
full-thickness region of the left ventricular septum was mea-
sured for each echo time using Thalassemia tools (a plug in
of CMRtools, Cardiovascular imaging solutions, London,
UK). Correction for positional changes between breath-holds
was made to ensure regions of interest were within the myocar-
dium. The accuracy of the T2* imaging is limited to the septum
due to susceptibility effect artifacts from anterior and posterior
cardiac veins and lungs that contaminate images of the other
LV regional walls.
To derive T2*, a mono-exponential trend-line was ﬁtted
with an equation in the form y= Ke_TE/T2* where K
Table 2 The correlation between serum ferritin level, liver and
myocardial T2* values.
Lab. test Patients N= 70
No. %
S. ferritin
Mild 12
Moderate 17.1
Severe 29
41.4
Min 29
Max 41.4
Mean ± SD 301
12,927
3.4 ± 2971
Myocardial T2*
Normal 57 81.4
Mild 5 7.1
Moderate 5 7.1
Severe 3 4.3
Role of MRI T2* in assessing iron concentration 1087represents a constant, TE represents the echo time and y rep-
resents the image signal intensity.
Analysis of the heart and liver T2* can be completed within
2 min. In heavily-iron loaded tissues, signal decay occurs
rapidly with noise dominating the signal at later echo times.
To minimize the potential for noise to cause over-estimation
of T2* in heavily iron-loaded tissues, these later points are
not used for curve ﬁtting for very low values of T2* and we
did truncation as He et al. (11).
For the measurement of liver T2*, a single trans-axial slice
through the center of the liver was imaged at 8 echo times (2.3–
16 ms). The TR was set to 200 ms without cardiac gating.
Signal intensity analysis was performed in the periphery of
the liver away from the large central vessels.
Cutoff points in this MRI instrument are as follows: liver:
normal >11.4 ms, mild: 3.8–11.4 ms, moderate: 1.8–3.8 ms,
severe: <1.8 ms. Cardiac: normal >20 ms, mild: 15–20 ms,
moderate: 10–15 ms, severe <10 ms.
2.2. Patients, and serum ferritin levels
Measurements were carried out by a microparticle enzyme
immunoassay technique (MEIA; Abbot Diagnostics, IMX
System, Ferritin, IL, USA).
3. Results
3.1. Patients
Seventy patients (36 males and 34 females) were evaluated in
this study. Their mean age was 19.34 ± 9.34. Splenectomy
had been performed in 12 of the patients. All patients had
received iron chelation therapy from early childhood for a
median duration of 18 months. The main characteristics of
these patients are summarized in Table 1.
3.1.1. Serum ferritin levels versus liver and myocardial T2*
values
Serum ferritin ranged between 301 and 12,927, with
mean ± SD (3.4 ± 2971). 17% of the patients showed mildTable 1 The socio-demographic characteristics of 70 patients.
Characteristics Patients N= 70
No. %
Age (years)
<10 9 12.9
10 47 67.1
P30 14 20.0
Min–max 5–49
Mean ± SD 19.34 ± 9.4
Gender
Male 36 51.4
Female 34 48.6
Education
Preschool 1 1.4
Primary 2 24.3
Secondary 3 71.4
Higher 4 2.9elevated ferritin level, while equal percentage (41%) had mod-
erate and severe high ferritin levels.
Myocardial T2* ranged from 32.14 to 12.0, and was at nor-
mal level among the majority of the patients (81.4%), while
7.1% presented with mild, and moderate each, while 4.3%
had severe myocardial iron overload with mean ± SD
(5.42 ± 60.0).
Regarding the liver, T2* ranged from 0.87 to 25.28 with
mean ± SD (5.3 ± 5.14) about third of the patients showed
mild and severe levels (30.0% and 35.7% respectively), moder-
ate hepatic T2* presented in 21.4% while only 12.9% showed
normal hepatic iron load.
The correlation between serum ferritin levels, hepatic and
cardiac MRI T2* is shown in Tables 2 and 3.
Serum ferritin levels showed a signiﬁcant negative correla-
tion with the liver T2* values (p 6 0.01, r= 0.318). (Fig. 1
and Tables 2 and 3).
No signiﬁcant correlation was found between serum ferritin
levels and myocardial T2*values (p= 0.528, r= 0.077).
(Fig. 2 and Tables 2 and 3).Mean ± SD 32.14 ± 12
Min–max 5.42–60.0
Liver T2*
Normal 9 12.9
Mild 21 30.0
Moderate 15 21.4
Severe 25 35.7
Mean ± SD 5.3 ± 5.14
Min–max 0.87–25.28
Table 3 Mean and standard deviation of serum ferritin, liver
and myocardial T2* values.
Parameters p value N= 70 r
Serum ferritin (Mean ± SD) 3.449 ± 2971
Liver T2* (Mean ± SD) 0.007* 5.3 ± 5.1 0.318
Myocardial T2* (Mean ± SD) 0.528 32.14 ± 12.05 0.077
1088 H.S. Fahmy et al.Patients with TM had higher serum ferritin levels than
patients with sickle cell disease. On the other hand, liver T2*
values were lowest in patient with TM and slightly higher in
those with SCD, but with no signiﬁcant difference. Heart
T2* values showed the same relations. We included only 5
cases of SCD out of 70 patients.
4. Discussion
The evaluation of tissue iron is essential for the determination
of clinical outcomes, deciding when to commence chelation
and for selection of the regime that should be prescribed.
The quantitative determination of the deposition of iron in
various organs in multi-transfused patients with thalassemia
and SCD is of outmost importance for the effective monitoring
of iron chelation therapy (12). Until recently, the liver iron
concentration was quantitated by biopsy, and ferritin levels
of the patient in steady state have been the only methods avail-
able to this effect. However, ferritin levels alone are not fully
acceptable because they may display considerable variations
due to inﬂammation, infection, or any other chronic disorders.
Moreover, there have been instances of heavy iron deposition,
where the serum ferritin levels were disproportionately low (7).
Tissue biopsy is the traditional gold standard for making
the diagnosis of myocardial iron overload (22), but iron depo-
sition tends to be patchy (7). Endomyocardial biopsies may
thus miss the areas of deposition and provide a false negative
result plus it is an invasive risky procedure (22).
The discomfort and risk that a liver biopsy causes to the
patients along with the weak correlation between liver ﬁbrosis
and iron concentration diminishes the value of this examina-
tion, especially when this has to be repeated serially (24).
Therefore, it is fully understandable that alternative, non-
invasive but accurate methods for the assessment of iron depo-
sition are in high demand over the last years.
Serial assessment of liver and cardiac iron demonstrates
that cardiac iron changes lag corresponding changes in liver
iron concentration. The liver is the dominant storage organ
for excess iron and readily acquires excess transferrin and non-
transferrin bound iron; it also mobilizes iron rapidly and efﬁ-
ciently in times of demand or in response to iron chelation. InFig. 1 Serum ferritin levels versus hepatic T2* values.contrast, the heart has robust mechanisms to prevent excess
transferring-mediated uptake (23). Pathologic myocardial iron
overload occurs when iron binding capacity is saturated and
labile free iron species begin to circulate. Even then, cardiac
iron uptake is delayed compared to many other extrahepatic
organs, including the pancreas. Thus many young patients
can exhibit severe hepatic iron overloading with no evidence
of cardiac iron overloading (28).
T2* is a fundamental MRI relaxation time that shortens in
the presence of iron. It is non-invasive, cost-effective, with no
radiation exposure and of widespread availability (25).
Anderson et al. were the ﬁrst to use the T2* technique for
myocardial iron assessment in subjects with thalassemia major
(1). It was observed that there was a progressive decline in ejec-
tion fraction of the heart as the myocardial iron deposition
increased and all patients with ventricular dysfunction had a
myocardial T2* of less than 20 ms (24).
The objective of our study was to reevaluate the effective-
ness of MRI in measuring the amount of iron deposited in
the heart and liver of regularly transfused patients with tha-
lassemia and SCD in our institute.
We included 70 patients with B-thalassemia and sickle cell
anemia (34 females and 36 males; 65 thalassemia patients
and 5 SCD), with a median age of 19.34 ± 9.34 (range: 5–
49 years). All patients were on regular transfusion programme
and on iron chelation therapy for at least 18 months.
Our data showed a strong correlation between LIC and
liver T2* for all groups of patients, which is in keeping with
the results of Kaltwasser et al. and Jensen et al. (12).
Our study also showed a strong negative correlation
between liver T2* and the serum ferritin levels in all patients.
Patients with T2*levels that indicated severe iron deposition
had corresponding low serum ferritin levels, which is in keep-
ing with the results of Fisher et al. (7). This indicates that
serum ferritin levels cannot predict the liver iron content
among patients.
However it was opposite to that by Eghbali et al. and that
of Christoforidis study in Greece which showed a strong pos-
itive correlation between hepatic T2* MRI and serum ferritin
levels (5,6).
Patients with negative correlation between liver T2* and
serum ferritin level, were given a higher dose of chelationFig. 2 Serum ferritin levels versus myocardial T2* values.
Role of MRI T2* in assessing iron concentration 1089therapy and followed by another MRI T2* after 6 months to
assess the effectiveness of the therapy.
No signiﬁcant correlation was found between serum ferritin
levels and myocardial T2* in our study. This is in line with
study done by Azarkeivan et al.: there was a moderate negative
correlation between serum ferritin and liver MRI T2* and a
poor correlation between serum ferritin and heart T2* (2).
Several other studies have found different correlation
strengths, ranging from no correlation to low correlation,
between serum ferritin and heart iron content; all have found
that serum ferritin cannot satisfactorily estimate cardiac
hemosiderosis (14,21).
Such results thus emphasizes the importance of MRI T2* as
a more accurate method for estimating liver and heart iron
overload.
Five cases showed severe cardiac overload with mild liver
iron overload and no corresponding high serum ferritin levels.
There have been reports of heavy cardiac iron deposition
despite the presence of low serum ferritin levels (1,19).
Noetzli et al. showed that low values of liver iron or serum fer-
ritin do not necessarily signify low-risk of iron-induced car-
diomyopathy. This may arise because iron chelation therapy
can remove iron more rapidly from the liver than from the
heart, which may normalize liver iron while myocardial iron
remains high (18).
T2* has been correlated to myocardial and hepatic iron
concentration in previous researches, including direct biopsies.
Recently, cardiac and liver iron estimates by MRI have
become the primary outcome measures for clinical studies of
iron chelation therapy (27). Ha et al. (10) stated that liver biop-
sies are now obsolete in thalassemia cases, except for histolog-
ical assessments of viral hepatitis.
4.1. Study limitations
Our study has a relatively small number of patients and lack of
consideration of intervening factors that may affect the serum
ferritin levels such as C-reactive protein, white blood cell count
and liver function tests.
5. Conclusion
MRI T2* provides accurate reproducible and non-invasive
technique for assessing tissue iron concentration saving the
patients invasive biopsy. Through the widespread application
of this technique it should be possible to improve management
of tissue iron overload, and in particular aid the presymp-
tomatic detection of myocardial siderosis, allowing earlier
chelation intensiﬁcation with its potential for reduced cardiac
events.Conﬂict of interest
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